On April 21, 2026 Ono Pharmaceuticals Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), reported two upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting to be held in Chicago, Illinois, from May 29 to June 2, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ONO-4578
Monday, June 1, 2026, 9:45 am to 12:45 pm CT, Oral Presentation
Abstract Number: 4007
Title: ONO-4578 combined with nivolumab and chemotherapy as first-line treatment for patients with HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: a randomized, double-blind, phase 2 trial (ONO-4578-08)
Presenter: Sung Hee Lim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Nivolumab (OPDIVO）
Monday, June 1, 2026, 9:45 am to 12:45 pm CT, Oral Presentation
Abstract Number: 4006
Title: Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: a randomized phase 3 trial (ATTRACTION-6)
Presenter: Do-Youn Oh, Seoul National University College of Medicine, Seoul, Republic of Korea
About ONO-4578
ONO-4578 is a selective, oral antagonist of EP4, which is one of the prostaglandin E2 (PGE2) receptors, developed by Ono. ONO-4578 is expected to exert antitumor effect by suppressing EP4-mediated effect of PGE2 and by restoring cancer immunity1). Based on the results of clinical trials in patients with gastric cancer that will be presented at ASCO (Free ASCO Whitepaper) 2026, we are currently working with our group company, Deciphera, to advance preparations for the initiation of a global Phase III clinical trial.
About nivolumab (OPDIVO）
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers since the approval for the treatment of melanoma in Japan in July 2014. Opdivo is currently approved in more than 65 countries, including Japan, South Korea, Taiwan, the US and European Union.
(Press release, Ono, APR 21, 2026, View Source [SID1234664641])